For decades, African nations have relied heavily on imported pharmaceuticals to meet their healthcare needs. Now, the continent stands at a crossroads: achieve medical self-sufficiency or remain shackled to global supply chains.
Why Africa must break free from pharmaceutical dependency
A mere handful of African countries operate production facilities capable of exporting beyond their borders. This leaves the continent importing 94% of its medicines—an annual expenditure exceeding $18 billion that could surge past $30 billion by 2030. The consequences extend beyond economics: structural dependence has created chronic vulnerabilities in healthcare systems.
More than 70% of public health facilities report critical stockouts at least once per quarter. Is it sustainable for 1.4 billion Africans to depend on industrial, logistical, and geopolitical decisions made outside the continent? The Covid-19 pandemic exposed harsh realities: shortages of essential drugs like amoxicillin, insulin, and anesthetics; astronomical price surges during crises; and crippled public health programs due to unavailable treatments. Yet Africa possesses untapped potential:
- A booming market: The pharmaceutical sector could exceed $70 billion by 2030.
- Rich biodiversity: Over 5,400 medicinal plants, some already integrated into official therapeutic protocols.
- Regulatory momentum: The African Medicines Agency (AMA), ratified by 27 nations, is standardizing norms.
- Political will: Countries like Burkina Faso, Rwanda, Egypt, Morocco, Senegal, and South Africa have launched ambitious local production initiatives.
Building Africa’s pharmaceutical industry from the ground up
A common misstep has been attempting to replicate multinational pharmaceutical models without establishing foundational capabilities. Industrialization demands more than imported equipment—it requires developing local human capital, technical expertise, and industrial assets.
Without addressing these core needs, local production often becomes costlier than imports, perpetuating dependence on foreign raw materials, technologies, and expertise. True pharmaceutical sovereignty requires rigorous, long-term strategies rooted in Africa’s unique strengths: growing markets, medicinal biodiversity, regulatory progress, and political commitment.
This path forward must prioritize incremental growth, starting with accessible and strategic segments. Africa’s pharmaceutical independence by 2045 isn’t just a goal—it’s a necessity to safeguard public health, stabilize economies, and secure a healthier future for generations to come.
Dr. Arnaud Kaboré
Pharmacist and Health Sector Executive Leader
